OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
Milton Packer, Javed Butler, Cordula Zeller, et al.
Circulation (2023) Vol. 148, Iss. 13, pp. 1011-1022
Open Access | Times Cited: 33
Milton Packer, Javed Butler, Cordula Zeller, et al.
Circulation (2023) Vol. 148, Iss. 13, pp. 1011-1022
Open Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
Kariem El‐Boghdadly, Jugdeep Dhesi, Philippa Fabb, et al.
Anaesthesia (2025)
Open Access | Times Cited: 8
Kariem El‐Boghdadly, Jugdeep Dhesi, Philippa Fabb, et al.
Anaesthesia (2025)
Open Access | Times Cited: 8
Acute kidney injury
Marlies Ostermann, Nuttha Lumlertgul, Rachel Jeong, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 241-256
Closed Access | Times Cited: 4
Marlies Ostermann, Nuttha Lumlertgul, Rachel Jeong, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 241-256
Closed Access | Times Cited: 4
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Veraprapas Kittipibul, Zachary L. Cox, Supavit Chesdachai, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 16, pp. 1568-1578
Closed Access | Times Cited: 15
Veraprapas Kittipibul, Zachary L. Cox, Supavit Chesdachai, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 16, pp. 1568-1578
Closed Access | Times Cited: 15
Risk of perioperative discontinuation of SGLT2 inhibitors
Maartina J.P. Oosterom-Eijmael, Jeroen Hermanides, Daniël H. van Raalte, et al.
British Journal of Anaesthesia (2024) Vol. 133, Iss. 2, pp. 239-240
Closed Access | Times Cited: 9
Maartina J.P. Oosterom-Eijmael, Jeroen Hermanides, Daniël H. van Raalte, et al.
British Journal of Anaesthesia (2024) Vol. 133, Iss. 2, pp. 239-240
Closed Access | Times Cited: 9
Frailty, Multimorbidity, and Polypharmacy
Kaitlin J. Mayne, Rebecca J. Sardell, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology (2024) Vol. 19, Iss. 9, pp. 1119-1129
Open Access | Times Cited: 6
Kaitlin J. Mayne, Rebecca J. Sardell, Natalie Staplin, et al.
Clinical Journal of the American Society of Nephrology (2024) Vol. 19, Iss. 9, pp. 1119-1129
Open Access | Times Cited: 6
Decongestion in acute heart failure: Is it time to change diuretic‐centred paradigm?
Jan Biegus, Gad Cotter, Marco Metra, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2094-2106
Open Access | Times Cited: 4
Jan Biegus, Gad Cotter, Marco Metra, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2094-2106
Open Access | Times Cited: 4
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
Mikhail Kosiborod, Sheryl L. Windsor, Orly Vardeny, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 10, pp. 725-734
Open Access | Times Cited: 4
Mikhail Kosiborod, Sheryl L. Windsor, Orly Vardeny, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 10, pp. 725-734
Open Access | Times Cited: 4
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction
Kerstin Piayda, Stefan Bertog, Kolja Sievert, et al.
JACC Heart Failure (2025)
Closed Access
Kerstin Piayda, Stefan Bertog, Kolja Sievert, et al.
JACC Heart Failure (2025)
Closed Access
Another Win for SGLT2 Inhibitors in Chronic Kidney Disease
David E. Leaf, Nisha Bansal
New England Journal of Medicine (2025) Vol. 392, Iss. 8, pp. 822-823
Closed Access
David E. Leaf, Nisha Bansal
New England Journal of Medicine (2025) Vol. 392, Iss. 8, pp. 822-823
Closed Access
Risk of perioperative discontinuation of SGLT2 inhibitors. Comment on Br J Anaesth 2024; 133: 239–40
Sarah Pearcey, Andrew P. Morris, Roger Knaggs
British Journal of Anaesthesia (2025)
Closed Access
Sarah Pearcey, Andrew P. Morris, Roger Knaggs
British Journal of Anaesthesia (2025)
Closed Access
SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review
Luminița Confederat, Oana-Maria Dragostin, Mihaela-Iustina Condurache
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1960-1960
Open Access
Luminița Confederat, Oana-Maria Dragostin, Mihaela-Iustina Condurache
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1960-1960
Open Access
Timing and Adherence Matter for Sodium–Glucose Cotransporter‐2 Inhibitors in Heart Failure
Mehmet Birhan Yılmaz, Ahmet Çelik, Anıl Şahin, et al.
Journal of the American Heart Association (2025)
Open Access
Mehmet Birhan Yılmaz, Ahmet Çelik, Anıl Şahin, et al.
Journal of the American Heart Association (2025)
Open Access
The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis
Reza Amani‐Beni, Bahar Darouei, Davood Shafie, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Reza Amani‐Beni, Bahar Darouei, Davood Shafie, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review
Yuxiang Luo, Wenbin Xiao, Yusuf Ziya Şener, et al.
European Journal of Heart Failure (2025)
Open Access
Yuxiang Luo, Wenbin Xiao, Yusuf Ziya Şener, et al.
European Journal of Heart Failure (2025)
Open Access
The ‘nephrotoxins’ were stopped: what is in a name and its impact on kidney and cardiac health?
Catherine D. Mao, Bobby Chacko
Internal Medicine Journal (2025)
Open Access
Catherine D. Mao, Bobby Chacko
Internal Medicine Journal (2025)
Open Access
The Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure
Masaki Nakagaito, Teruhiko Imamura, Ryuichi Ushijima, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3196-3196
Open Access | Times Cited: 3
Masaki Nakagaito, Teruhiko Imamura, Ryuichi Ushijima, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3196-3196
Open Access | Times Cited: 3
How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient?
Bruno Garcia, Marlies Ostermann, Matthieu Legrand
Intensive Care Medicine (2024)
Open Access | Times Cited: 3
Bruno Garcia, Marlies Ostermann, Matthieu Legrand
Intensive Care Medicine (2024)
Open Access | Times Cited: 3
Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure
Angela Duvalyan, Ricardo M. La Hoz, Darren K. McGuire, et al.
Journal of Cardiac Failure (2024) Vol. 30, Iss. 8, pp. 1031-1040
Closed Access | Times Cited: 2
Angela Duvalyan, Ricardo M. La Hoz, Darren K. McGuire, et al.
Journal of Cardiac Failure (2024) Vol. 30, Iss. 8, pp. 1031-1040
Closed Access | Times Cited: 2
Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis
Jingjin Hou, Li Ren, Qingbin Hou, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Jingjin Hou, Li Ren, Qingbin Hou, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 2
A Systematic Review and Meta-analysis on the Safety and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitor Use in Hospitalized Patients
Frank Gao, Aleena S. Ali, Rinaldo Bellomo, et al.
Diabetes Care (2024) Vol. 47, Iss. 12, pp. 2275-2290
Closed Access | Times Cited: 2
Frank Gao, Aleena S. Ali, Rinaldo Bellomo, et al.
Diabetes Care (2024) Vol. 47, Iss. 12, pp. 2275-2290
Closed Access | Times Cited: 2
Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction
Khawaja M. Talha, Javed Butler, Milton Packer
Journal of the American College of Cardiology (2024)
Open Access | Times Cited: 1
Khawaja M. Talha, Javed Butler, Milton Packer
Journal of the American College of Cardiology (2024)
Open Access | Times Cited: 1
Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus
Juan José Gorgojo Martínez, José Luis Górriz, Ana María Cebrián Cuenca, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6509-6509
Open Access | Times Cited: 1
Juan José Gorgojo Martínez, José Luis Górriz, Ana María Cebrián Cuenca, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6509-6509
Open Access | Times Cited: 1
Using combinational diuretics across the spectrum of renal function
Pieter Martens, Wilfried Müllens
European Journal of Heart Failure (2023) Vol. 25, Iss. 10, pp. 1794-1796
Open Access | Times Cited: 1
Pieter Martens, Wilfried Müllens
European Journal of Heart Failure (2023) Vol. 25, Iss. 10, pp. 1794-1796
Open Access | Times Cited: 1
EMPEROR: Empaglifozin-Effekte verschwinden nach Abbruch der Behandlung bei Herzinsuffizienz
Johannes B. Dahm
Aktuelle Kardiologie (2024) Vol. 13, Iss. 01, pp. 22-22
Closed Access
Johannes B. Dahm
Aktuelle Kardiologie (2024) Vol. 13, Iss. 01, pp. 22-22
Closed Access
Impact of Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure
Masaki Nakagaito, Teruhiko Imamura, Ryuichi Ushijima, et al.
(2024)
Open Access
Masaki Nakagaito, Teruhiko Imamura, Ryuichi Ushijima, et al.
(2024)
Open Access
